We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Sensus Healthcare, Inc. (SRTS) Moves 7.3% Higher: Will This Strength Last?
Read MoreHide Full Article
Sensus Healthcare, Inc. (SRTS - Free Report) shares rallied 7.3% in the last trading session to close at $11.84. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 14.2% gain over the past four weeks.
Sensus Healthcare scored a strong price increase after the news regarding one Mata Mata species of turtle being successfully treated with the company’s SRT-100 system surfaced. In June 2021, Sensus Healthcare’s proprietary superficial radiation therapy (SRT) was applied to the turtle’s squamous cell carcinoma. The turtle did not exhibit any signs of the lesion three months post treatment and has remained cancer-free till date. It is worth noting that the mata mata turtle has been added to the increasing list of animal species successfully treated with Sensus Healthcare’s SRT-100 system.
This company is expected to post quarterly earnings of $0.06 per share in its upcoming report, which represents a year-over-year change of +185.7%. Revenues are expected to be $6.24 million, up 103.1% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Sensus Healthcare, Inc., the consensus EPS estimate for the quarter has been revised 1100% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on SRTS going forward to see if this recent jump can turn into more strength down the road.
Sensus Healthcare, Inc. belongs to the Zacks Medical - Instruments industry. Another stock from the same industry, Artivion (AORT - Free Report) , closed the last trading session 2.3% higher at $20.25. Over the past month, AORT has returned 7.3%.
For Artivion, the consensus EPS estimate for the upcoming report has changed +33.3% over the past month to -$0.04. This represents a change of +50% from what the company reported a year ago. Artivion currently has a Zacks Rank of #3 (Hold).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Sensus Healthcare, Inc. (SRTS) Moves 7.3% Higher: Will This Strength Last?
Sensus Healthcare, Inc. (SRTS - Free Report) shares rallied 7.3% in the last trading session to close at $11.84. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 14.2% gain over the past four weeks.
Sensus Healthcare scored a strong price increase after the news regarding one Mata Mata species of turtle being successfully treated with the company’s SRT-100 system surfaced. In June 2021, Sensus Healthcare’s proprietary superficial radiation therapy (SRT) was applied to the turtle’s squamous cell carcinoma. The turtle did not exhibit any signs of the lesion three months post treatment and has remained cancer-free till date. It is worth noting that the mata mata turtle has been added to the increasing list of animal species successfully treated with Sensus Healthcare’s SRT-100 system.
This company is expected to post quarterly earnings of $0.06 per share in its upcoming report, which represents a year-over-year change of +185.7%. Revenues are expected to be $6.24 million, up 103.1% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Sensus Healthcare, Inc., the consensus EPS estimate for the quarter has been revised 1100% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on SRTS going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Sensus Healthcare, Inc. belongs to the Zacks Medical - Instruments industry. Another stock from the same industry, Artivion (AORT - Free Report) , closed the last trading session 2.3% higher at $20.25. Over the past month, AORT has returned 7.3%.
For Artivion, the consensus EPS estimate for the upcoming report has changed +33.3% over the past month to -$0.04. This represents a change of +50% from what the company reported a year ago. Artivion currently has a Zacks Rank of #3 (Hold).